Turquoise Biotechnologies
Sydney, Australia· Est.
Exosome‑engineered delivery platform for targeted therapeutics across oncology and autoimmune diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Exosome‑engineered delivery platform for targeted therapeutics across oncology and autoimmune diseases.
OncologyImmunologyGastroenterologyNeurologyCardiology
Technology Platform
Engineered exosomes bearing custom surface ligands deliver small molecules, RNA, DNA, or CRISPR components directly to target cells, enabling precise, low‑immunogenicity therapeutic delivery.
Opportunities
Scalable exosome platform can accelerate development of multiple targeted therapeutics and attract partnerships with pharma seeking advanced delivery solutions.
Risk Factors
Technical challenges in large‑scale exosome manufacturing, payload loading efficiency, and regulatory approval could delay clinical translation.
Competitive Landscape
Key competitors include exosome‑focused firms such as Exosome Therapeutics and Codiak BioSciences; Turquoise differentiates through its modular targeting ligands and dual drug‑ and gene‑delivery capabilities.